Tuesday, 2 February 2021

Innovation in real-time next-generation sequencing provides pharmaceutical benefits


Tim Sandle explains how next-generation sequencing (NGS) could aid in the development of novel antimicrobials to overcome multi-drug resistance.

Sandle, T. (2021) Innovation in real-time next-generation sequencing provides pharmaceutical benefits, European Pharmaceutical Review at: https://www.europeanpharmaceuticalreview.com/article/138807/innovation-in-real-time-next-generation-sequencing-provides-pharmaceutical-benefits/

Sepsis is a life-threatening condition that occurs when the body’s immune system overreacts to an infection and begins to damage its own tissues and organs. Identifying the causative microbial agent and treating it is essential for treating septicaemia (bacterial infections of the bloodstream – bacteraemia – are the most common forms of sepsis). Finding improved means for accelerating the diagnosis of sepsis is of vital importance to ensure that the patient is administered the correct medicine. If the wrong medicine is given, or if the selection of the medicine is delayed, this can result in patient death, depending on the severity as measured by the sequential organ failure assessment score. Many diagnostic tests are limited in terms of their time-to-result or they are simply not sufficiently specific to provide the necessary output. 



Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

No comments:

Post a comment

Pharmaceutical Microbiology Resources

Special offers